Project Grant R01HL187149
Award Date 8/1/26
Completion Date 5/31/30
Dollars Obligated $754K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45206, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Emory University $198,728 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of claudin11 in regulating endothelial barrier function in sepsis. The research examines how the tight junction protein claudin11 forms a signaling hub with pannexin1 to regulate vascular barrier function in response to inflammatory cytokines associated with sepsis. Sepsis affects approximately 1.7...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $715,504 for Project Grant R01HL187582 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will investigate the regulation of long-lasting hematopoietic multipotent progenitors (MPPs) and the mechanisms by which immune signals shape their functional properties. The research addresses evolving understanding of hematopoietic cell production dynamics,...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $4,349,952 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the phosphorylation-based molecular and functional mechanisms by which cardiac myosin binding protein C (CMYBP-C) modulates cardiac contractile function. The research employs a multidisciplinary experimental approach spanning atomic to whole-organ scales to determine how CMYBP-C conformational changes in...
- The National Heart, Lung, and Blood Institute awarded the University of Cincinnati Sponsored Research Services Division $1.57 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on targeted rewiring of fibrosis drivers to enhance cardiac reprogramming following myocardial infarction. The research addresses excessive cardiac fibrosis resulting from the heart's repair response, which can lead to adverse remodeling and heart failure. The...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the Department of Health and Human Services National Institutes of Health, awarded The Medical College of Wisconsin, Inc. $792,011 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to validate plasma cell-free DNA (CFDNA)—including nuclear and mitochondrial variants—as a clinically actionable biomarker for predicting critical post-surgical events in infants undergoing complex congenital heart surgery....
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $770,000 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research unraveling endothelial-cardiomyocyte crosstalk in cardiomyopathy using an integrated multimodal approach. The research examines molecular mechanisms by which endothelial dysfunction contributes to cardiac dysfunction in cardiomyopathy, focusing on cell-to-cell signaling between endothelial cells...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart, Lung, and Blood Institute awarded New York University $836,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial mechanosensing of circulatory flow in health and disease. The project will examine how endothelial cells lining blood and lymphatic vessels respond to fluid flow forces, with focus on the roles of PLXND1 (a transmembrane semaphorin receptor) and KLF2 (a transcription factor) in endothelial responses to...